Interleukin-27 receptor (IL-27R) (IL-27R)

The Interleukin-27 receptor (IL-27R) is a heterodimeric type I cytokine receptor composed of the IL-27 receptor alpha subunit (IL-27RA, also known as WSX-1 or TCCR) and the glycoprotein 130 (gp130) subunit [3, 4, 15]. It is primarily expressed on various immune cells, including T cells, B cells, macrophages, and dendritic cells [2, 7, 15]. Upon binding its ligand, IL-27, the receptor activates the JAK/STAT signaling pathway, particularly STAT1 and STAT3, to modulate immune responses [2, 4, 7, 15]. IL-27R signaling plays a dual role, promoting Th1 cell differentiation and anti-tumor immunity while also exerting anti-inflammatory effects by inhibiting Th17 differentiation and inducing IL-10 production [1, 4, 7, 11, 13]. Due to its involvement in cancer, autoimmune diseases, and infectious conditions like sepsis, the IL-27 receptor is a significant therapeutic target for both agonistic and antagonistic strategies [2, 7, 11, 16, 20].

Other names

IL-27 receptor complexWSX-1/gp130 complexTCCR/gp130 complexIL-27RA/gp130 complexCytokine receptor WSX-1Type I T-cell cytokine receptor (TCCR)ZcytoR1

Agonism to enhance Th1-mediated anti-tumor immunity or suppress Th17-driven inflammation; Antagonism to block pro-inflammatory signaling or immune checkpoint activity in specific disease contexts.